EDSA - Edesa Biotech Inc Stock Price, Fair Value and News

4.61USD+0.10 (+2.22%)Market Closed

Market Summary

USD4.61+0.10

Market Closed

2.22%

EDSA Stock Price

View Fullscreen

EDSA RSI Chart

EDSA Valuation

Market Cap

14.5M

Price/Earnings (Trailing)

-2

Price/Sales (Trailing)

24.96

EV/EBITDA

-1.52

Price/Free Cashflow

-2.29

EDSA Price/Sales (Trailing)

EDSA Profitability

Operating Margin

100.00%

EBT Margin

-1359.52%

Return on Equity

-167.54%

Return on Assets

-111.89%

Free Cashflow Yield

-43.71%

EDSA Fundamentals

EDSA Revenue

Revenue (TTM)

581.0K

Rev. Growth (Yr)

906.35%

Rev. Growth (Qtr)

151.59%

EDSA Earnings

Earnings (TTM)

-7.2M

Earnings Growth (Yr)

20.26%

Earnings Growth (Qtr)

-10.9%

Breaking Down EDSA Revenue

52 Week Range

4.77

(Low)(High)

Last 7 days

-0.9%

Last 30 days

-0.7%

Last 90 days

-6.6%

Trailing 12 Months

355.6%

How does EDSA drawdown profile look like?

EDSA Financial Health

Current Ratio

1.97

EDSA Investor Care

Shares Dilution (1Y)

9.35%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	713.9K	647.4K	581.0K	0
2022	4.0M	2.6M	780.3K	0
2021	7.4M	8.6M	10.3M	11.1M
2020	576.2K	568.4K	328.8K	0
2019	298.1K	0	465.1K	518.7K
2018	108.0K	160.5K	211.8K	244.4K
2017	662.1K	501.5K	228.3K	106.9K
2016	1.2M	1.2M	1.3M	925.4K
2015	604.1K	681.4K	758.7K	1.0M
2014	387.0K	379.6K	372.1K	526.8K
2013	0	0	409.4K	402.0K
2012	0	0	286.1K	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Edesa Biotech Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	nijhawan pardeep	acquired	-	-	3,083	chief executive officer
Apr 01, 2024	nijhawan pardeep	acquired	-	-	3,253	chief executive officer
Mar 25, 2024	nijhawan pardeep	bought	20,000	4.00	5,000	chief executive officer
Mar 01, 2024	nijhawan pardeep	acquired	-	-	2,765	chief executive officer
Feb 01, 2024	nijhawan pardeep	acquired	-	-	2,978	chief executive officer
Jan 08, 2024	nijhawan pardeep	acquired	-	-	2,908	chief executive officer
Aug 04, 2023	nijhawan pardeep	acquired	-	-	99,300	chief executive officer
Aug 04, 2023	lemieux stephen	acquired	-	-	17,400	chief financial officer
Aug 04, 2023	brooks michael j	acquired	-	-	93,200	president

Which funds bought or sold EDSA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	AllSquare Wealth Management LLC	unchanged	-	-1.00	4.00	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 23, 2024	FIFTH THIRD BANCORP	unchanged	-	-38.00	419	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-12.00	105	-%
Apr 01, 2024	Global Wealth Strategies & Associates	sold off	-100	-32.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-70,065	-	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	74,697	74,697	-%
Feb 14, 2024	Velan Capital Investment Management LP	sold off	-100	-809,981	-	-%
Feb 14, 2024	Royal Bank of Canada	new	-	1,000	1,000	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-1,000	-	-%

Are Funds Buying or Selling EDSA?

Are funds buying EDSA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EDSA

No. of Funds

Unveiling Edesa Biotech Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 29, 2024	velan capital investment management lp	1.97%	63,492	SC 13G/A
Jan 16, 2024	pardeep nijhawan medicine professional corp	11.1%	353,007	SC 13D/A
Aug 21, 2023	pardeep nijhawan medicine professional corp	12.2%	2,592,118	SC 13D/A
Jan 13, 2023	lumira capital investment management inc.	8.2%	1,600,932	SC 13D/A
Jan 06, 2023	velan capital investment management lp	8.78%	1,777,776	SC 13G
Nov 08, 2022	pardeep nijhawan medicine professional corp	13.2%	2,592,118	SC 13D/A
Sep 18, 2020	edesa biotech, inc.	22.3%	2,135,594	SC 13D/A
Feb 11, 2020	intracoastal capital, llc	0%	0	SC 13G/A
Jan 23, 2020	10379085 canada inc.	7.8%	690,843	SC 13D/A
Jan 16, 2020	lumira capital investment management inc.	20.7%	1,833,066	SC 13D/A

Recent SEC filings of Edesa Biotech Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
May 01, 2024	4	Insider Trading
Apr 05, 2024	DEFA14A	DEFA14A
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	ARS	ARS
Apr 02, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Feb 09, 2024	8-K	Current Report

Peers (Alternatives to Edesa Biotech Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.2B	2.0B	-2.86%	-28.22%	-57.69	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.54	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	-0.76%	-10.51%	28.42	4.5	60.38%	-34.49%
NVAX	627.6M	996.6M	1.36%	-50.17%	-1.57	0.63	-26.66%	65.49%
CRBP	467.5M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	260.8M	4.9M	-4.04%	14.81%	-1.93	53.59	-54.97%	51.71%
IBIO	6.4M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

Edesa Biotech Inc News

Latest updates

Edesa Biotech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	151.6%	304,002	120,834	90,626	60,417	30,209	-	-	-	780,257	1,863,578	1,306,796	7,170,465	500	109,985	110,516	107,800	240,082	117,755	53,033	54,257	73,053
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	2,314	1,472	10,037	3,778	101,286	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	9,510,431	2,010,974	1,878,419	1,626,768	1,213,482	1,381,378	540,778	405,741	1,240,370	421,993
S&GA Expenses	-100.0%	-	1,152,971	1,416,264	1,038,587	952,391	1,042,381	1,249,982	1,532,416	1,210,677	1,356,753	1,608,232	1,535,127	853,889	733,079	1,113,917	681,706	798,295	429,076	148,350	1,181,137	123,770
R&D Expenses	67.0%	1,176,337	704,458	953,399	1,025,622	1,458,190	1,793,930	4,547,543	3,042,815	3,951,046	4,127,767	4,464,347	7,975,304	1,154,771	1,143,868	502,814	527,998	481,797	111,702	257,391	664,272	298,223
EBITDA Margin	11.2%	-13.22	-14.89	-14.92	-19.70	-21.56	-22.08	-7.25	-3.96	-1.14	-1.23	-1.16	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	800	-	-	-	800	-	-	800	-	-	-	800	-	-	-	800	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-1,860,531	-	-1,720,343	-1,984,906	-2,333,549	-2,813,911	-5,787,020	-4,568,516	-	-4,176,608	-4,759,510	-2,259,187	-	-	-	-	-	-1,656,477	-1,404,904	-1,129,004	-1,156,672
EBT Margin	10.8%	-13.60	-15.24	-15.24	-19.95	-21.72	-22.23	-7.30	-3.99	-1.16	-1.24	-1.17	-	-	-	-	-	-	-	-	-	-
Net Income	-10.9%	-1,861,331	-1,678,451	-1,720,343	-1,984,906	-2,334,349	-2,813,911	-5,787,020	-4,569,316	-4,378,677	-3,686,041	-4,759,510	-2,259,987	-2,013,698	-1,765,763	-1,489,636	-1,094,333	-953,897	-528,830	-364,849	-1,129,004	-411,840
Net Income Margin	6.1%	-12.47	-13.28	-14.41	-14.62	-18.59	-22.49	-6.97	-4.40	-1.36	-1.29	-1.36	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-18.0%	-1,660,159	-1,406,528	-1,468,022	-1,805,221	-1,572,145	-5,628,166	-3,028,185	-417,853	-3,210,754	-353,857	-3,123,066	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-17.3%	6,475	7,832	8,890	9,420	10,673	11,675	11,576	17,541	20,408	12,343	14,585	16,877	24,002	10,291	10,762	8,923	7,633	5,089	5,718	7,228	9,151
Current Assets	-21.7%	4,242	5,416	6,437	6,914	8,130	9,087	9,092	15,180	18,000	9,892	12,091	14,334	21,418	7,667	8,104	6,221	7,426	4,827	5,645	7,124	8,139
Cash Equivalents	-34.4%	2,800	4,268	5,361	6,457	7,471	8,270	7,091	12,809	15,887	5,881	7,839	8,053	10,966	6,305	7,214	5,641	6,990	3,827	5,031	6,363	3,042
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78.00	244
Net PPE	-10.1%	7.00	8.00	9.00	10.00	11.00	12.00	13.00	15.00	16.00	17.00	15.00	18.00	16.00	15.00	15.00	20.00	25.00	48.00	73.00	89.00	997
Liabilities	8.2%	2,151	1,987	1,842	1,569	1,674	1,401	2,184	5,704	3,383	1,794	1,526	1,074	4,729	1,033	1,654	1,123	702	856	462	-	-
Current Liabilities	8.2%	2,151	1,987	1,822	1,529	1,565	1,280	2,141	5,657	3,335	1,747	1,459	983	4,620	906	1,530	983	579	704	462	1,015	881
Shareholder's Equity	-26.0%	4,324	5,845	7,049	7,850	9,000	10,273	9,391	11,837	17,024	10,549	13,058	15,804	19,273	7,885	6,631	5,342	6,931	4,234	5,256	6,213	2,772
Retained Earnings	-3.4%	-55,958	-54,097	-52,418	-50,698	-48,713	-46,379	-44,044	-41,230	-35,443	-30,874	-26,495	-22,809	-18,050	-15,784	-13,132	-11,099	-9,318	-7,828	-6,734	-5,780	-53,493
Additional Paid-In Capital	1.1%	13,373	13,224	13,039	12,598	12,490	12,418	11,176	12,930	12,364	5,481	4,871	4,006	2,914	2,157	1,550	1,952	1,881	337	328	318	-
Shares Outstanding	1.6%	3,216	3,165	3,075	2,981	2,866	2,765	2,380	2,209	2,209	1,931	1,899	1,894	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	-	-	35,987	-	-	-	42,403	-	-	-	8,423	-	-	-	5,758

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-18.0%	-1,660	-1,406	-1,468	-1,805	-1,572	-1,791	-5,628	-3,026	-416	-3,207	-355	-3,119	-7,179	-3,010	-1,672	-1,353	-1,170	-789	-1,326	-3,119	-398
Share Based Compensation	-18.8%	150	184	517	108	288	334	456	565	630	609	905	1,100	467	723	142	11.00	380	9.00	-45.68	123	13.00
Cashflow From Investing	-	-	-	-	-	-	-	41*	-1.36	-1.20	-3.14	1.00	-3.51	-2.96	-1.13	4.00	-26.83	520	-477	13.00	6,407	-1.50
Cashflow From Financing	-30.8%	212	306	412	741	765	2,912	-286*	-	10,401	1,229	221	16.00	11,943	1,995	3,228	-27.49	3,847	45.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EDSA Income Statement

2023-12-31

Condensed Interim Consolidated Statements of Operations - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Expenses:
Research and development	$ 704,458	$ 1,357,338
General and administrative	1,152,971	1,020,967
Loss from operations	(1,857,429)	(2,378,305)
Other income (loss):
Reimbursement grant income	120,834	0
Interest income	60,966	49,429
Foreign exchange loss	(2,822)	(5,941)
Non-operating Income	178,978	43,488
Net loss	(1,678,451)	(2,334,817)
Exchange differences on translation	(572)	(25,067)
Net comprehensive loss	$ (1,679,023)	$ (2,359,884)
Weighted average number of common shares	3,128,024	2,626,847
Loss per common share - basic and diluted	$ (0.54)	$ (0.89)

EDSA Balance Sheet

2023-12-31

Condensed Interim Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 4,267,787	$ 5,361,397
Accounts and other receivable	743,569	626,543
Prepaid expenses and other current assets	404,903	448,912
Total current assets	5,416,259	6,436,852
Non-current assets:
Property and equipment, net	8,188	8,702
Long-term deposits	177,731	173,490
Intangible asset, net	2,154,727	2,180,020
Right-of-use assets	74,885	91,373
Total assets	7,831,790	8,890,437
Current liabilities:
Accounts payable and accrued liabilities	1,908,598	1,747,150
Short-term right-of-use lease liabilities	78,314	74,714
Total current liabilities	1,986,912	1,821,864
Non-current liabilities:
Long-term right-of-use lease liabilities	0	19,773
Total liabilities	1,986,912	1,841,637
Shareholders' equity:
Capital shares Authorized unlimited common and preferred shares without par value Issued and outstanding: 3,164,722 common shares (September 30, 2023 - 3,075,473)	46,933,895	46,643,151
Additional paid-in capital	13,223,622	13,039,265
Accumulated other comprehensive loss	(215,220)	(214,648)
Accumulated deficit	(54,097,419)	(52,418,968)
Total shareholders' equity	5,844,878	7,048,800
Total liabilities and shareholders' equity	$ 7,831,790	$ 8,890,437

About Edesa Biotech Inc

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

CEO	Dr. Pardeep Nijhawan FRCPC, M.D.
WEBSITE	edesabiotech.com
INDUSTRY	Biotechnology
EMPLOYEES	16

Edesa Biotech Inc Frequently Asked Questions

What is the ticker symbol for Edesa Biotech Inc? What does EDSA stand for in stocks?

EDSA is the stock ticker symbol of Edesa Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Edesa Biotech Inc (EDSA)?

As of Thu May 09 2024, market cap of Edesa Biotech Inc is 14.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EDSA stock?

You can check EDSA's fair value in chart for subscribers.

What is the fair value of EDSA stock?

You can check EDSA's fair value in chart for subscribers. The fair value of Edesa Biotech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Edesa Biotech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EDSA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Edesa Biotech Inc a good stock to buy?

The fair value guage provides a quick view whether EDSA is over valued or under valued. Whether Edesa Biotech Inc is cheap or expensive depends on the assumptions which impact Edesa Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EDSA.

What is Edesa Biotech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, EDSA's PE ratio (Price to Earnings) is -1.85 and Price to Sales (PS) ratio is 23.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EDSA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Edesa Biotech Inc's stock?

In the past 10 years, Edesa Biotech Inc has provided -0.367 (multiply by 100 for percentage) rate of return.